Genomma Lab Internacional SAB de CV Class B · BMV:LAB/B
Genomma Lab Internacional SAB de CV Class B — Investor Presentation (November 2014)
26 slides from Genomma Lab Internacional SAB de CV Class B's investor presentation, November 2014

Slide 1: Corporate Presentation November 2014
EXPORTING WELL- NOVEMBER 2014) 3 S +s : LATAM

Slide 2: Company Overview
NVEIOEIOOIOD Fi aS | b ee | | 5 Fee Noma SS Sistema 4 | Ge | SON Iran a 7 | ye “ | vince I AL \ J ' BoA EN _2. COMPAN OVERVIEW 9)" (9

Slide 3: Company history and acquisitions
Acquisition of 2 packages of brands in our international operations Entrance to IPC Sustainability Index and MSCI Index Acquisition of the brands: Fermodyl, Zan Zusi, Altiva, Amara, Larizá, Bioskin and XL-3 in Mexico, Babysan and Piecidex in Argentina and Dermaglós in Brazil Acquisition of Marzam Ac

Slide 4: IPO and index inclusion
¢ In 2008, Genomma Lab conducted its Initial Public Offering in the Mexican Stock Exchange (BMV). ¢ In 2010, it entered the Mexican Stock Index (IPC) of the BMV. ¢Genomma Lab is one of the most liquid companies in the BMV. ¢ The Company is part of the MSCI EM LATAM Mid Cap Index and MSCI Mexico Stan

Slide 5: Unique product development and innovation capabilities
Bo UNIQUE PRODUCT DEVELOPMENT AND INNOVATION CAPABILITIES Genomma Lab (“Genomma”) is a leading Pharmaceutical and Personal Care products (“PC”) company in Mexico with international operations in Latin America and the United States. It is one of the fastest growing companies in the industry. S vi IN-

Slide 6: Manufacturing and product development pillars
Best formulation and Performance presentation Analysis (Product Selection) MANUFACTURING DEVELOPMENT INNOVATION & MARKETING & DISTRIBUTION OUTSOURCED ASSURANCE BRANDING QUALITY SALES Impressively short lead time Rapid and effective from an idea generation to new reaction to competitive product launc

Slide 7: SKUs
Offers branded OTC Offers over 100 Focuses on topical pharmaceuticals in SKU’s under the dermatological, facial variety of forms brand Primer Nivel and hair treatments Por Tu Salud and other categories - Inhibitors of gastric - Varicose vein secretions - Anti-rheumatics treatment - Hemorrhoid - Anti

Slide 8: Top 25 brands
Genomma's core asset is its portfolio of market leading brands. As of September 2014, the Company has a total of 91 brands. The following table shows the Company’s top 25 brands for the last twelve months as of September 2014, which represented 82.1% of Total Sales. Sexual Protection and Anti-scar,

Slide 9: Advertising strategy
Demand for our products is mainly generated through advertising. We have a directed advertising strategy, based on metric analyses of our clients and the market. We monitor such information weekly, which allows us to have a quick response to changes in competition and consumer’s preferences.

Slide 10: Competitive Position
| 2. COMPETIT POSITION = Duele (]

Slide 11: Market position versus competitors
(For the last twelve months, as of September 2014) Genomma Lab Bayer Boehringer Sanofi Aventis Shering Plough Pisa Reckitt Benckiser Novartis Wyeth Johnson Johnson Source: IMS Health.

Slide 12: Market share
Source: Company data and IMS Health.

Slide 13: Market share
Source: Company data and IMS Health..

Slide 14: Rankings by country and category
OTC – Over the Counter Pharma – OTC and Generics PC Phar m a – Personal Care PC 1. Brazil 2. OTC Argentina PC 3. USA 4. Colombia 5. Chile 6. Peru 7. Ecuador *According to IMS.

Slide 15: Diversified distribution platform
DIVERSIFIED DISTRIBUTION PLATFORM DISTRIBUTION IN MEXICO: 4% 18% 39% *As of September 2014 (LTM) Genomma’s balanced and broad distribution platform is unique. Through a combination of mass merchandisers, pharmacy chains, and wholesalers, Genomma’s products reach over 44,000 points of sale in Mexico,

Slide 16: International operations and brands by country
Bolivia Chile Brands: 19 Costa Rica Dominican Republic Ecuador El Salvador Guatemala Honduras Brands: 91 Nicaragua Brands: 13 Panama Paraguay Peru Uruguay Brands: 26 Brands: 12 Brands: 25

Slide 17: Growth strategy
• Innovation & Development • Entrance to new segments • Broad Distribution • Formula Improvement • Line Extensions • Revitalize Acquired Brands • Brand Development • Implement Marketing Capabilities • International Expansion

Slide 18: 3Q14 LTM
*CAGR from 2008 to 2013 2008 2009 2010 2011 2012 2013 3Q14 LTM

Slide 19: Product launches
Nasal Hygiene For adults For children Nasalub Max Vitamins Energetic beverage Vitamins for with vitamins children

Slide 20: Product launches
X-Ray with added Calcium and Vitamin D Osteoarthritis treatment for diabetics Osteoarthritis Joint pain treatment relief

Slide 21: Genomma Lab Internacional
Genomma Lab’ Internacional

Slide 22: Revenue by segment and region
YoY Growth: 9.5% 2008 2009 2010 2012 2013 2011 3Q13 3Q14 3Q14 3Q13 Pharma* PC Total 3Q14 Pharma* PC Total 3Q13 %Var Mexico 1,339.0 675.6 2,014.6 1,197.7 819.4 2,017.1 -0.1% International 379.0 966.0 1,344.9 240.2 809.4 1,049.6 28.1% TOTAL 1,718.0 1,641.5 3,359.5 1,437.9 1,628.8 3,066.8 9.5%

Slide 23: EBITDA and margin
3,500 50.0% 3,000 YoY Growth: 2,500 40.0% 6.8% 2,000 30.0% 1,500 20.0% 1,000 10.0% 500 - 0.0% 2008 2009 2010 2012 2013 2011 3Q13 3Q14 EBITDA EBITDA MARGIN

Slide 24: Quarterly results
1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14

Slide 25: Net income as % of revenue
YoY Growth: 1.3% 2013 2008 2009 2010 2012 2011 3Q13 3Q14 NET INCOME AS % OF REVENUE

Slide 26: Investor relations website
i= =. z www.genommalab.com/inversionistas . ¢
Source: Internet Archive copy of inversionistas.genommalab.com
More decks from Genomma Lab Internacional SAB de CV Class B
Q3 2026 Earnings Presentation27 slides · Apr 1, 2026
Q2 2026 Earnings Presentation29 slides · Apr 1, 2026
Investor Presentation (December 2025)32 slides · December 2025
Q3 2025 Earnings Presentation26 slides · October 2025
Q2 2025 Earnings Presentation33 slides · July 2025
Q1 2025 Earnings Presentation58 slides · May 2, 2025